Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

487.40 +17.13 (+3.64%)
Streaming Delayed Price Updated: 11:17 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
3 Pharma Stocks That Could See a Surge in Demand in 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead 
Via InvestorPlace
How To Attend Alnylam Pharmaceuticals Q1 2023 Earnings Conference Call
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
 
Via Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
 
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
 
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
 
Via Benzinga
Alnylam Pharmaceuticals's Return On Capital Employed Insights
 
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
 
Via Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
 
Via Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all... 
Via Benzinga
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
 
Via Benzinga
Five Best And Worst Performing Healthcare Stocks In December 2022
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
3 Growth Stocks That Could Rocket Higher in 2023
Upcoming binary events could push these stocks to new all-time highs. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
 
Via Benzinga
Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday
 
Via Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
 
Via Benzinga
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter. 
Via Benzinga
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program
 
Via Benzinga
Alnylam Pharmaceuticals: Q3 Earnings Insights
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
Where Alnylam Pharmaceuticals Stands With Analysts
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company
  
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
Bear market, shmear market. These biotech stocks are soaring despite the market downturn. 
Via The Motley Fool
Where Alnylam Pharmaceuticals Stands With Analysts
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.